Dompe Farmaceutici SpA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Dompe Farmaceutici SpA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10825
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イタリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Dompe Farmaceutici SpA (Dompe) is a developer of therapeutic solutions that research novel therapies for the treatment of rare and orphan diseases. The company provides product pipeline such as C5aR Antagonists, TRPM8 Blockers pain, TRPM8 Blockers urology, BKB1R Antagonists, CNR2 Agonists and GPR120 Agonists, among others. It offers treatment in the therapeutic areas of respiratory diseases, chronic obstructive pulmonary disease, pulmonary arterial hypertension, cystic fibrosis, osteoarticular solutions, pain therapy and dentistry, among others. Dompe’s target research areas include respiratory diseases, oncology, diabetology, ophthalmology, organ transplantation, chronic obstructive pulmonary disease and pulmonary arterial hypertension, among others. The company has operations in the US and Albania. Dompe is headquartered in Milan, Italy.

Dompe Farmaceutici SpA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Dompe Farmaceutici to Acquire Pharma Division of Bracco 10
Partnerships 11
Bracco Imaging Enters into Agreement with Shanghai Pharma 11
Lubris Biopharma Enters into Agreement with Dompe Farmaceutici 12
Dompe Farmaceutici Enters into Distribution Agreement with Omega Pharma 13
Dompe Farmaceutici Enters Into Co-Development Agreement With SatRx For Reparixin 14
Licensing Agreements 15
MolMed and Dompe Expand Licensing and Distribution Agreement 15
Debt Offering 16
Bracco Imaging Raises USD124.6 Million in Private Placement of 3.17% Notes Due 2021 16
Asset Transactions 17
Dompe Farmaceutici to Acquire Pharma Division of Bracco 17
Acquisition 18
Dompe Acquires Remaining 51% Stake In Anabasis 18
Dompe Farmaceutici SpA – Key Competitors 19
Dompe Farmaceutici SpA – Key Employees 20
Dompe Farmaceutici SpA – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Key Facts 2
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Dompe Farmaceutici SpA, Deals By Therapy Area, 2012 to YTD 2018 8
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Dompe Farmaceutici to Acquire Pharma Division of Bracco 10
Bracco Imaging Enters into Agreement with Shanghai Pharma 11
Lubris Biopharma Enters into Agreement with Dompe Farmaceutici 12
Dompe Farmaceutici Enters into Distribution Agreement with Omega Pharma 13
Dompe Farmaceutici Enters Into Co-Development Agreement With SatRx For Reparixin 14
MolMed and Dompe Expand Licensing and Distribution Agreement 15
Bracco Imaging Raises USD124.6 Million in Private Placement of 3.17% Notes Due 2021 16
Dompe Farmaceutici to Acquire Pharma Division of Bracco 17
Dompe Acquires Remaining 51% Stake In Anabasis 18
Dompe Farmaceutici SpA, Key Competitors 19
Dompe Farmaceutici SpA, Key Employees 20
Dompe Farmaceutici SpA, Other Locations 21
Dompe Farmaceutici SpA, Subsidiaries 21

List of Figures
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Dompe Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Dompe Farmaceutici SpA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SK Biopharmaceuticals Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary SK Biopharmaceuticals Co Ltd (SK Biopharmaceuticals), a subsidiary of SK Holdings Co Ltd is a researcher and developer of drugs. The company develops and markets drugs for the treatment of central nervous system. It provides plumiaz, SKL-N05 and JZP-110; YKP3089, relenopride, SKL-PD, SKL-A4R …
  • International SOS Pte Ltd:企業の戦略的SWOT分析
    International SOS Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Avid Technology Inc (AVID):企業の財務・戦略的SWOT分析
    Avid Technology Inc (AVID) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • GrafTech International Ltd:企業の戦略・SWOT・財務情報
    GrafTech International Ltd - Strategy, SWOT and Corporate Finance Report Summary GrafTech International Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Shopper’s Stop Ltd.:企業の戦略・SWOT・財務情報
    Shopper's Stop Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shopper's Stop Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Columbia Sportswear Co (COLM):企業の財務・戦略的SWOT分析
    Columbia Sportswear Co (COLM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Perenco Holdings:企業の戦略的SWOT分析
    Perenco Holdings - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Co-Diagnostics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Co-Diagnostics Inc (Co-Diagnostics) is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The company’s products include HCV RNA real-time PCR kit, HIV RNA real-time PCR kit, malaria DNA real-time PCR kit, and TB complex DNA kit …
  • HSBC Trinkaus & Burkhardt AG (TUB):企業の財務・戦略的SWOT分析
    HSBC Trinkaus & Burkhardt AG (TUB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • ARYZTA AG:企業のM&A・事業提携・投資動向
    ARYZTA AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ARYZTA AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • MYnd Analytics Inc (MYND):医療機器:M&Aディール及び事業提携情報
    Summary MYnd Analytics Inc (MYnd Analytics), formerly CNS Response Inc, is a predictive analytics company. The company develops a decision support tool that assists physicians in the provision of personalized medication for individual patients suffering from mental health issues. It provides Psychia …
  • Aspyrian Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Aspyrian Therapeutics Inc (Aspyrian Therapeutics) is a clinical stage biotechnology company that develops first-in-class precision targeted cancer drugs for the treatment of solid tumors. The company harnesses the Photoimmunotherapy (PIT) platform to develop its products. Its lead pipeline p …
  • McAfee, Inc.:企業の戦略的SWOT分析
    McAfee, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • EBN B.V.:石油・ガス:M&Aディール及び事業提携情報
    Summary EBN BV (EBN) is an independent oil and natural gas company that carries out exploration, production, storage and trading of oil and natural gas. The company participates in nearly all the exploration and production activities in the Netherlands through a public-private partnership model. It …
  • CMP Pharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CMP Pharma Inc (CMP Pharma), formerly Carolina Medical Products Company Inc is a specialty pharmaceutical company that develops and manufactures generic prescription, non-prescription and skin care products. The company’s prescription products include SPS suspension, isoniazid oral solution …
  • Banco de Sabadell SA:企業のM&A・事業提携・投資動向
    Banco de Sabadell SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Banco de Sabadell SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • IRB Infrastructure Developers Ltd:企業の戦略・SWOT・財務情報
    IRB Infrastructure Developers Ltd - Strategy, SWOT and Corporate Finance Report Summary IRB Infrastructure Developers Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Griffon Corporation:企業の戦略・SWOT・財務情報
    Griffon Corporation - Strategy, SWOT and Corporate Finance Report Summary Griffon Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • National Institute of Neurological Disorders and Stroke-製薬・医療分野:企業M&A・提携分析
    Summary National Institute of Neurological Disorders and Stroke (NINDS), a subsidiary of National Institutes of Health is a healthcare research institute that conducts and supports research on brain and nervous system disorders. The institute’s clinical research areas include Alzheimer’s disease, br …
  • Fluor Corp (FLR):企業の財務・戦略的SWOT分析
    Fluor Corp (FLR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆